Key result
Ruling out suspected pulmonary embolism by a normal D-dimer combined with a low or moderate clinical probability was safe, with a 3-month thromboembolic risk of 0% (95% CI, 0.0-5.6%).
Why the study?
Does a normal D-dimer combined with low or moderate clinical probability safely rule out pulmonary embolism in patients with suspected PE?
Observational (n=202)
Does a normal D-dimer combined with low or moderate clinical probability safely rule out pulmonary embolism in patients with suspected PE?
Ruling out suspected PE using a normal D-dimer combined with low or moderate clinical probability is a safe and efficient strategy with a 0% 3-month thromboembolic risk.
Supports D-dimer rule-out in low/moderate-probability suspected PE; leaves open need for larger prospective validation.
D-dimer test combined with clinical probability assessment has been proposed as the first step in the diagnostic work-up of patients with suspected pulmonary embolism (PE). In a prospective management study we investigated the safety and efficiency of excluding PE by a normal D-dimer combined with a low or moderate clinical probability. Of the 202 study patients this combination ruled out PE in 64 (32%) patients. The 3-month thromboembolic risk in these patients was 0% (95% CI, 0.0-5.6%). The prevalence of PE in the entire cohort was 29% (59 patients), whereas in the low, moderate and high clinical probability groups this was 25%, 26% and 50%, respectively. We conclude that ruling out suspected PE by a normal D-dimer combined with a low or moderate clinical probability appears to be a safe and efficient strategy. The accuracy of the clinical probability assessment is modest.
No takes yet. Share an insight, caveat, or question.
Lutisan et al. (2003) conducted an observational in Suspected pulmonary embolism (n=202). Normal D-dimer combined with low or moderate clinical probability was evaluated on 3-month thromboembolic risk (95% CI 0.0-5.6). Ruling out suspected pulmonary embolism by a normal D-dimer combined with a low or moderate clinical probability was safe, with a 3-month thromboembolic risk of 0% (95% CI, 0.0-5.6%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: